MicroPort EP announced today that it received EU MDR certification for its PulseMagic pulsed field ablation (PFA) catheter. The China-based company designed its PFA catheter to enhance both flexibility and performance in electrophysiology (EP) procedures. MicroPort says that PulseMagic enables both high-density mapping and PFA through one … [Read more...] about MicroPort EP wins European approval for PFA catheter
Pulsed Field Ablation
Haemonetics wins expanded FDA nod for vascular closure system in PFA, LAAC to treat AFib
Haemonetics (NYSE:HAE) announced today that it received FDA approval to expand the labeling for its Vascade MVP XL system. Expanded labeling includes procedures using 10-14F inner diameter (ID) and up to 17F outer diameter (OD) procedural sheaths. This grants Vascade MVP XL approval for larger sheaths used in market-leading technologies used for … [Read more...] about Haemonetics wins expanded FDA nod for vascular closure system in PFA, LAAC to treat AFib
Luma Vision expands clinical program, submits latest Verafeye tech to FDA
Luma Vision announced today that it expanded its clinical program following the latest submission of its Verafeye platform to the FDA. Dublin, Ireland-based Luma Vision develops the Verafeye 4D navigation and imaging platform. The company designed Verafeye to guide catheter ablation therapy. That includes pulmonary vein isolation, posterior wall … [Read more...] about Luma Vision expands clinical program, submits latest Verafeye tech to FDA
Pulse Biosciences shifts focus to accelerate cardiac pulsed field ablation program
Pulse Biosciences (Nasdaq:PLSE) announced a new strategic alignment to focus on its nPulse cardiac catheter ablation system. Hayward, California-based Pulse said it wants to prioritize and accelerate the development and future commercialization of nPulse. As a result, the company plans to centralize resources on the cardiac catheter platform, … [Read more...] about Pulse Biosciences shifts focus to accelerate cardiac pulsed field ablation program
Endogenex has positive data for pulsed electric field tech for diabetes
Endogenex today announced new findings supporting its technology for improving outcomes in individuals with type 2 diabetes. Minneapolis-based Endogenex develops the Endogenex ReCET technology, which uses electroporation therapy to achieve re-cellularization. It utilizes non-thermogenic pulsed electric fields (PEF) to regenerate duodenal mucosal … [Read more...] about Endogenex has positive data for pulsed electric field tech for diabetes
PFA tech developer Field Medical names new CEO
Field Medical announced today that it named Dr. Mark A. Turco as CEO, effective immediately. Turco brings more than 30 years of leadership experience to the pulsed field ablation (PFA) technology developer. It was founded by Dr. Steven Mickelsen, who also serves as chief technology officer. Mickelsen previously founded Farapulse, which Boston … [Read more...] about PFA tech developer Field Medical names new CEO
Stereotaxis expects growth in 2026 with manufacturing ramp for new products
Stereotaxis (NYSE:STXS) today reported its fourth-quarter and full-year financial results ahead of expected growth in 2026. The company reported fourth-quarter revenue totaling $8.6 million, marking a 36% increase year-over-year. However, that fell shy of Wall Street expectations for $9.24 million. St. Louis-based Stereotaxis reported total 2025 … [Read more...] about Stereotaxis expects growth in 2026 with manufacturing ramp for new products
Pulse Biosciences has positive data for thyroid nodule ablation
Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse Vybrance system. Long-term follow-up data came from the nPulse Vybrance percutaneous electrode system first-in-human ablation study. It evaluated the ablation of benign thyroid nodules using nanosecond pulsed field ablation (nsPFA) … [Read more...] about Pulse Biosciences has positive data for thyroid nodule ablation
Boston Scientific wins expanded CE mark for Farapulse in persistent AFib
Boston Scientific (NYSE: BSX) announced today that its Farapulse pulsed field ablation (PFA) system received expanded CE mark approval. The PFA system earned expanded labeling in Europe to include the treatment of persistent AFib, according to a LinkedIn post. "This approval represents an important step forward in addressing the evolving … [Read more...] about Boston Scientific wins expanded CE mark for Farapulse in persistent AFib
Boston Scientific Farapulse PFA outperforms thermal ablation in study
Boston Scientific (NYSE:BSX) has announced new data backing its Farapulse pulsed field ablation (PFA) platform for treating AFib. Farapulse, a nonthermal treatment, uses electric fields to selectively ablate heart tissue. It's one of the leading PFA systems in a market that includes Medtronic, Johnson & Johnson … [Read more...] about Boston Scientific Farapulse PFA outperforms thermal ablation in study
